Get the Stockscreener App
7.01
6.53%
-0.49
After Hours:
7.05
0.04
+0.57%
Cybin Inc stock is traded at $7.01, with a volume of 1.31M.
It is down -6.53% in the last 24 hours and down -4.63% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$7.50
Open:
$7.6
24h Volume:
1.31M
Relative Volume:
4.74
Market Cap:
$147.42M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-33.75
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
+6.37%
1M Performance:
-4.63%
6M Performance:
-37.19%
1Y Performance:
-47.44%
1-Day Range:
$6.8916
$7.70
1-Week Range:
$6.25
$7.70
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.01 | 138.56M | 0 | -52.07M | -44.93M | -0.2077 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Acce - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics | CYBN Stock News - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
(CYBN) Investment Analysis - news.stocktradersdaily.com
Cybin, Inc: Covering All Bases as Commercialization Preparations Continue - Smartkarma
Cboe Canada Single Security - Cboe Global Markets
Cybin partners with Thermo Fisher for Phase 3 drug production By Investing.com - Investing.com Nigeria
Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment - simplywall.st
Cybin (CYBN) Collaborates with Thermo Fisher for Phase 3 Development | CYBN Stock News - GuruFocus
CYBN Gains on Thermo Fisher Partnership for CYB003 Production - GuruFocus
AGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset - Endpoints News
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 (CYBN:NYSE) - Seeking Alpha
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program - marketscreener.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Man - GuruFocus
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin partners with Thermo Fisher for Phase 3 drug production - Investing.com
Cybin Inc. Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for Its Cyb003 Program for the Adjunctive Treatment of Major Depressive Disorder - marketscreener.com
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase | CYBN Stock News - GuruFocus
Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment - TipRanks
Cybin (OTCMKTS:CYBN) Shares Down 0.5% – Time to Sell? - Defense World
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin secures new patent for depression treatment drug - Investing.com
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - BioSpace
Cybin (CYBN) Secures U.S. Patent for CYB003 Program | CYBN Stock News - GuruFocus
Cybin secures new patent for depression treatment drug By Investing.com - Investing.com Nigeria
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder - marketscreener.com
Trading (CYBN) With Integrated Risk Controls - news.stocktradersdaily.com
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
Marshall Wace LLP Makes New Investment in Cybin Inc. (NYSE:CYBN) - Defense World
Should You Buy, Sell, or Hold AppLovin Stock Before Q1 Earnings? - The Globe and Mail
Psychedelic drug developer Cybin partners with Osmind - MSN
Cybin (CYBN) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Participate at the 28th Annual Milken Institute Global Conference | CYBN Stock News - GuruFocus
Cybin to Participate at the 28th Annual Milken Institute Global Conference - Bluefield Daily Telegraph
ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI - The Globe and Mail
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin (NYSE:CYBN) Trading Up 2.9% – Here’s What Happened - Defense World
Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa
Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Prog - GuruFocus
Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus
Cybin advances Phase 3 trial for depression treatment - Investing.com
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025 - marketscreener.com
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
1.09%
Cap:
|
Volume (24h):